Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2017 Feb 1;24(4):R81–R97. doi: 10.1530/ERC-16-0482

Table 3.

siRNA nanoparticle strategies to augment proposed TNBC subtype-specific therapies

TNBC subtype Current proposed therapy Proposed siRNA nanoparticle strategy
Basal-like Cisplatin siBRCA + cisplatin
Mesenchymal PI3K/mTOR inhibitor sip110β + MEK inhibitor
siPIK3CA mutant + chemo
siGF combination
siEMT combination
Luminal androgen receptor Bicalutamide siAR

GF – growth factor; EMT – Epithelial-mesenchymal transition; AR – Androgen receptor